Michael Gertner MD is the founder and inventor of the iTEAR technology. He receivd his MD at Cornell University and completed his residency in General Surgery at UCSF. He studied mechanical and biomedical engineering at Columbia and obtained a masters at MIT. He co-founded the Surgical Innovation Program at Stanford which ultimately merged into the Biodesign Innovation Program. He is the first inventor on over 200 patents, and author of over 3 dozen journal articles and book chapters.
Micheal Fulton - Founding Investor
Dr. Fulton is a Senior Managing Director at Biostar Capital and a founding investor in Olympic Ophthalmics. He has spent his entire career in healthcare, including over 20 years as a successful early-stage investor and entrepreneur. Prior to joining BioStar, Dr. Fulton was a Managing Director of Hopen Life Science Ventures, a healthcare-focused venture capital firm. Dr. Fulton received his B.A. from Northwestern University and his M.D. from Cornell University Medical College. He also completed two years of neurosurgery training at the Cleveland Clinic.
Louie Cannon - Founding investor
Louis Cannon, MD, is a founding investor of Olympic Opthalmics through his role as the founder and senior managing director at BioStar Capital and the BioStar Ventures Funds . He holds medical device patents, is the Founder and President of the Cardiac and Vascular Research Center of Northern Michigan and has been repeatedly honored as one of "America’s Top Interventional Cardiologists.” A previous Judah Folkman scholar in residence he has authored hundreds of articles for medical publications and has served on the advisory boards for Fortune 500 companies such as Medtronic, Abbott, Boston Scientific, Johnson and Johnson, and Covidien, as well as many early developing medical technology companies. He recently served on the public BOD of Corindus (CVRS : NYSE), recently acquired by Siemens Healthineers (OTC: SMMNY) which had over a 500 % increase in market cap over 2 years since his joining the BOD.
Immanuel Thangaraj - Founding investor
Mr. Thangaraj is a founding investor in Olympic Ophthalmics. He has 20 years of experience as a seasoned investor in operations, venture capital and growth equity opportunities. He began his career at ARCH Venture Partners (“AVP”), a leading venture capital firm with over $2 billion under management which makes early stage technology and healthcare investments. Next, he was a managing director at Essex Woodlands Health Ventures for over 20 years. Mr. Thangaraj was an early investor and board member of Tear Science (acquired by JnJ) and serves on the Board of Directors for Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), Serene LLC, Kona Medical, Inc., and Proteus Digital Health. He serves as the Co-Chair of the Council of the Booth School of Business and the Visiting Committee of the College, both at the University of Chicago. He is also a Trustee of Trinity School in Menlo Park, California; on the Board of the India Community Center in Milpitas, California; and the former Chairman of MAP International. Mr. Thangaraj holds both a Bachelor of Arts degree and a Master of Business Administration degree from the University of Chicago.